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ABSTRACT
Studies of gene fusions in solid tumors are not
as extensive as in hematological malignancies due
to several technical and analytical problems asso-
ciated with tumor heterogeneity. Nevertheless,
there is a growing interest in the role of fusion
genes in common epithelial tumors after the discov-
ery of recurrent TMPRSS2:ETS fusions in prostate
cancer. Among all of the reported fusion partners
in the ETS gene family, TMPRSS2:ERG is the most
prevalent one. Here, we present a simple and sensi-
tive microarray-based assay that is able to simulta-
neously determine multiple fusion variants with a
single RT–PCR in impure RNA specimens. The
assay detected TMPRSS2:ERG fusion transcripts
with a detection sensitivity of _10 cells in the pres-
ence of more than 3000 times excess normal RNA,
and in primary prostate tumors having no `1% of
cancer cells. The ability to detect multiple transcript
variants in a single assay is critically dependent
on both the primer and probe designs. The assay
should facilitate clinical and basic studies for
fusion gene screening in clinical specimens, as it
can be readily adapted to include multiple gene loci.
INTRODUCTION
Chromosome rearrangements are a characteristic feature
of cancer. More than 350 gene fusions, as a consequence
of chromosome aberrations, have been identiﬁed (1).
While gene fusions are common in hematological malig-
nancies, their presence in solid tumors is not as well stu-
died due to several technical and analytic problems related
to tumor heterogeneity (1). Only very limited gene fusion
events were discovered in solid tumors, mostly in sarco-
mas, until the recent discovery of TMPRSS2:ETS fusion
genes in prostate cancer (2). This ﬁnding has since
changed the general view that gene fusions play only a
minor role in the pathogenesis of epithelial tumors.
Therefore, there is renewed interest in searching for
fusion genes in solid tumors, due to their potential
impact on basic research and clinical application as has
been demonstrated in chronic myelogenous leukemia
(CML) (3,4).
The recurrent gene fusion event in prostate cancer
involves an androgen controlled gene, TMPRSS2, and
members (ERG, ETV1 and ETV4) of the ETS transcrip-
tion factor family (2,5,6). Among these fusion genes,
TMPRSS2:ERG is the most prevalent and the only
member detected in the majority of reports. This fusion
transcript results from  3Mb interstitial deletion between
these two loci at chromosome 21q22. It was found in
approximately half (15–78%) of all prostate cancers
(2,6–17). As an androgen-related transcription factor
controlling cell proliferation, TMPRSS2:ERG has been
associated with disease pathogenesis and is a promising
biomarker for prostate cancer progression, prognosti-
cation and early detection (18–21). While the presence of
TMPRSS2:ETS fusion genes is highly prostate cancer-
speciﬁc, its signiﬁcance as a prognostic biomarker is still
controversial partly because many of the clinical studies
have been relatively small scale. Therefore, it is important
to develop a simple and robust assay for identifying var-
ious TMPRSS2:ETS and potential fusion genes in other
solid tumors. However, this could be challenging due to
high heterogeneity in prostate cancer and other solid
tumors, compared to leukemias and lymphomas (22).
Several approaches that have been used previously for
hematological malignancies have been applied to detect
TMPRSS2:ERG exon fusion variants. These include
ﬂuorescent in situ hybridization (FISH) (2,12,14,17,23),
RT–PCR and sequencing (2,7,9,13), quantitative PCR
(qPCR) (2,8,24) and array-based comparative genome
hybridization (array CGH) (10–12). FISH may be the
most commonly used method, but it has relatively low
resolution, and therefore, cannot accurately determine
diﬀerent fusion variants. Array CGH has a higher
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RT–PCR and qPCR are relatively easy to perform.
However, to assess multiple potential fusion variants
requires multiple sets of primers and probes, and a corre-
sponding large quantity of RNA templates. Moreover,
sequencing RT–PCR products is laborious and diﬃcult
to adapt in routine clinical laboratories. Here, we describe
an exon array-based detection system, combined with a
RT–PCR reaction, that accurately determines multiple
TMPRSS2:ERG fusion transcripts in specimens with
only a minor population of tumor cells. The method
adopts several features of the Virochip (25) protocol to
establish a speciﬁc, sensitive and semi-quantitative assay
that is very useful for analyzing highly heterogeneous solid
tumors.
MATERIALS AND METHODS
RNA isolation
The cell lines described in the article were obtained from
the American Type Culture Collection (ATCC, Manassas,
VA, USA) and cultured as recommended. Frozen unpur-
iﬁed prostate tissues were obtained during routine surgery,
and classiﬁed pathologically by one of us. The total RNA
was extracted with Trizol (Invitrogen, Carlsbad, CA,
USA) following the manufacturer’s instructions. The pri-
mary tumor samples were puriﬁed by Qiagen RNeasy mini
kit (Qiagen, Valencia, CA, USA).
Microarrays
The exon and junction probes are 30-mer oligonucleotides
synthesized by Integrated DNA Technologies (Coralville,
IA, USA) or Illumina/Invitrogen (San Diego, CA, USA)
and printed on poly-L-lysine slides at 50mM along with
Human Cot-1 DNA (Invitrogen), which is enriched for
repetitive sequences, and herring sperm DNA (Promega,
Madison, WI, USA), which was used as nonspeciﬁc con-
trol. The printing procedure has been described and essen-
tially follows the manual of the DeRisi arrayer with silicon
microcontact printing pins (Parallel Synthesis Technolo-
gies, Inc. Santa Clara, CA, USA) (25–27). Arrays were
postprocessed with succinic anhydride-based method for
blocking before hybridization as previously described (27).
The protocols related to array printing and hybridization
in this article generally can be found in the following link:
http://cat.ucsf.edu/equipment/arrayer/index.html.
Probelabeling
The RT–PCR reaction was performed with an OneStep
RT-PCR kit (Qiagen) essentially following the manufac-
turer’s protocol, except that the ﬁnal reaction volume was
scaled down to 20ml. The forward (GTT TCC CAG TCA
CGA TCC AGG AGG CGG AGG CGG A) and reverse
primers (GTT TCC CAG TCA CGA TCG GCG TTG
TAG CTG GGG GTG AG) are located at exon 6 of ERG
and exon 1 of TMPRSS2 respectively, as described (2,9).
The 50-ends of both primers have the sequence of primer
B (GTT TCC CAG TCA CGA TC) for the subsequent
step of PCR labeling with a single primer B as described
previously (25).
The procedure is a modiﬁcation of the previously
reported ‘Round ABC’ protocol (25). Brieﬂy, the RT–
PCR reaction was assembled at 48C in a PCR workstation
and transferred to a thermocycler with the block pre-
heated to 508C. The initial reverse transcription was per-
formed at 508C for 30min and followed by 958C for
15min to activate HotStarTaq DNA polymerase as well
as to inactivate the reverse transcriptases (Round A). The
PCR conditions were 35 cycles at 928C for 30s, 558C for
30s and 688C for 1.5min with a ﬁnal extension step at
688C for 5min (Round B). One microliter of unpuriﬁed
product was subsequently used as a template for another
20 cycles of ampliﬁcation to label the amplicons via a
previously described ‘Round C’ PCR protocol (948C for
30s, 408C for 30s, 508C for 30s and 728C for 1min) with
primer B and a 4:1 mixture of aminoallyl dUTP (Ambion,
Austin, TX, USA) and dTTP for probe labeling (25). The
labeled amplicons were puriﬁed with DNA Clean-up and
Concentrator-5 columns (Zymo Research, Orange, CA,
USA), eluted in 9ml of sodium bicarbonate (pH 9.0) and
coupled with 1ml of DMSO dissolved Cy3 NHS esters
(GE Healthcare, Piscataway, NJ, USA) for 30–60min.
The Cy3-labeled amplicons were puriﬁed with DNA
Clean-up and Concentrator-5 columns and eluted with
10ml of 10mM Tris–HCl (pH 8.0). Then, the Cy3-labeled
amplicons were diluted in water and combined with 3.6ml
of 20  SSC, 0.5ml of HEPES (pH 7.0) and ﬁnally 0.5ml
of 10% SDS to reach ﬁnal volume of 25ml. The mixed
solution was heated for 2min at 958C, cooled to room
temperature and hybridized to the exon mapping arrays
at 638C overnight essentially as previously described
(25–27). The hybridized arrays were washed and scanned
with a GenePix 4000B scanner (Molecular Device,
Sunnyvale, CA, USA) and analyzed by GenePix Pro 6.0
software.
2D DNA-FISH
Frozen prostate cancer samples were sectioned onto slides.
Cell nuclei were isolated in situ with ice-cold cytoskeleton
buﬀer (CSK: 300mM sucrose, 100mM NaCl, 10mM
PIPES, 3mM MgCL2, 1mM EGTA and 0.5% Triton
X-100) (28). The slides were ﬁxed by dipping in ice-cold
methanol for 3min, followed by ice-cold acetone. After
air drying the slides, they were allowed to age for at
least 1 week in ethanol.
DNA-FISH was carried out according to a method for
single copy loci detection (28). The protocol was adapted
with few modiﬁcations, using 50-mer oligonucleotides
speciﬁc to the loci of interest and labeled with a desired
hapten. Two probes were used for FISH for break-
apart assay. A probe located at the promoter region of
TMPRSS2 was labeled with biotin (Bio/GACTCCA
GGAGCGCTCCCCAGAATCCCCTTCCTTAACCCA
AACTCGAGCC). The other probe at exon 2 of ERG was
labeled with 50-6-carboxyﬂuorescein (56FAM) (56FAM/
GATCTTTGGAGACCCGAGGAAAGCCGTGTTGA
CCAAAAGCAAGACAAATG). Detection of probes was
achieved by using antibodies conjugated to quantum dots
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mized to use a combination of two antibodies (1:200)
obtained from Invitrogen–Molecular Probes
TM (Qdot
655
 sheep anti-Bio primary antibody conjugate; Qdot
525
 Goat anti-FITC whole IgG primary antibody conju-
gate). Image acquisition was done with a Zeiss Axioplan
2e microscope (Carl Zeiss, Inc.). All pictures in the corre-
sponding three channels were deconvolved and optical
sections merged to produce 2D pictures using Axiovision
4.0 software (Carl Zeiss, Inc.) and Image J (Rasband, W.S.,
ImageJ, U. S. National Institutes of Health, Bethesda,
MD, USA, http://rsb.info.nih.gov/ij/, 1997–2006.)
RESULTS
Microarray-based TMPRSS2:ERG exon fusion mapping
To develop a multiplexing assay that is highly sensitive in
clinical samples of high complexity, we adopted our
Virochip system (25). The key protocol, Round ABC,
designed for unbiased ampliﬁcation (29), is crucial for
identifying various fusion variants in this application.
Through literature review, we found that most of the
TMPRSS2:ERG fusion junctions are between exons 1 or 2
of the TMPRSS2 and exons 2–5 of the ERG (2,7,9,13).
Such constraints perhaps are related to whether a func-
tional ERG protein can be made from the gene fusions (9).
Therefore, we initially used a pair of primers at exon 1 of
the TMPRSS2 and exon 6 of the ERG for RT–PCR. As
shown in Figure 1A, PCR products were only generated
when there was a gene fusion, since the two primers
are located at diﬀerent genes. Subsequently, the PCR
products were labeled and hybridized to an exon array
for mapping the exons near the fusion junction. Printed
on the array are 30-mer oligonucleotide probes derived
from exons 1–3 of the TMPRSS2 and exons 1–5 of the
ERG (Table 1). Each selected sequence is represented by
two complementary probes (F: forward and R: reverse
complement) since sometimes PCR-labeled amplicons
may bind to only one strand of the probe, based on
empirical observations (25). We observed that probes
with reverse complementary (R) orientation worked con-
sistently with our RT–PCR labeling protocol.
A prostate cancer cell line, VCaP, (30) with a
TMPRSS2 and ERG fusion (2) was used for initial feasi-
bility testing. The total RNA was subjected to RT–PCR
with a pair of primers located at exon 6 of ERG and exon
1 of TMPRSS2 (2,9). The unpuriﬁed product was labeled
and hybridized on the microarray (Figure 1B). Only spots
corresponding to exon 1 of TMPRSS2 and exons 4–5 of
ERG developed strong signals. This result indicates the
fusion junction is at the exon 1 of TMPRSS2 and exon
4 of ERG, which is consistent with a previous report (2).
To mimic a typical clinical situation, in which small
population of cancer cells are present among normal
host cells in a primary tumor, we spiked decreasing
amounts of total RNA extracted from VCaP cells into
an excess of HeLa RNA, which does not have the fusion
transcripts. The detection limit is 32pg of VCaP RNA in
the presence of 100ng of HeLa RNA (Figure 2). This
translates into only 1–3 cancer cells in the presence of
3000 times more normal cells. The level of sensitivity is
superior to previous methods for detecting fusion tran-
scripts (24).
TMPRSS2:ERG fusion junction mappingin primary
prostate cancer
To test the ability of the exon mapping array to detect
and characterize TMPRSS2:ERG fusion transcripts in
clinical samples, we isolated total RNA from frozen unpur-
iﬁed primary prostate tissues obtained during surgery.
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Figure 1. TMPRSS2:ERG exon mapping strategy. (A) The RT–PCR is
performed using a 30 primer from exon 6 of the ERG and a 50 primer
from exon 1 of the TMPRSS2. Only fusion transcripts can be exponen-
tially ampliﬁed since the two primers are at diﬀerent genes. The probes
on the array are derived from exons 1–3 of the TMPRSS2 and exons
1–5 of the ERG (Table 1). (B) The hybridization pattern of RT–PCR
labeled amplicons with total RNA derived from the VCaP cell line.
The result clearly shows that the fusion junction is at exon 1 of the
TMPRSS2 and exon 4 of the ERG, as illustrated in the fusion scenario
in (A). A probe that spans on the junction of exon 1 and 2 of the
TMPRSS2 is labeled as ‘1/2’.
Table 1. Exon probes
Name Sequence
T1F GGGCGGGGAGCGCCGCCTGGAGCGCGGCAG
T2F ACATTCCAGATACCTATCATTACTCGATGC
T3F GGTCACCACCAGCTATTGGACCTTACTATG
T1/2F TGGAGCGCGGCAGGTCATATTGAACATTCC
G1F AGGGACATGAGAGAAGAGGAGCGGCGCTCA
G2F AGACCCGAGGAAAGCCGTGTTGACCAAAAG
G3F GCTGGTAGATGGGCTGGCTTACTGAAGGAC
G4F TTATCAGTTGTGAGTGAGGACCAGTCGTTG
G5F CTCTCCTGATGAATGCAGTGTGGCCAAAGG
T1R CTGCCGCGCTCCAGGCGGCGCTCCCCGCCC
T2R GCATCGAGTAATGATAGGTATCTGGAATGT
T3R CATAGTAAGGTCCAATAGCTGGTGGTGACC
T1/2R GGAATGTTCAATATGACCTGCCGCGCTCCA
G1R TGAGCGCCGCTCCTCTTCTCTCATGTCCCT
G2R CTTTTGGTCAACACGGCTTTCCTCGGGTCT
G3R GTCCTTCAGTAAGCCAGCCCATCTACCAGC
G4R CAACGACTGGTCCTCACTCACAACTGATAA
G5R CCTTTGGCCACACTGCATTCATCAGGAGAG
T, TMPRSS2; G, ERG. F, forward probe; R, reverse comple-
ment probe.
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stromal cells. Total RNA (5–50ng) from prostate cancers
(n=20) and nonmalignant hyperplastic prostate tissues
(n=10) were subjected to RT–PCR labeling and array
hybridization. The results showed that 7/20 cancers but
0/10 nonmalignant samples had TMPRSS2:ERG fusion
genes. To conﬁrm the presence of the gene fusions, direct
sequencing was performed for the seven samples. The
sequencing data validated the exon fusion ﬁndings revealed
by the array assays. Similar to other reports (7,12,13),
some samples clearly showed two or more bands on
the agarose gel when the PCR products were subjected
to electrophoresis, corresponding to two or more fusion
transcripts in the same specimens.
The multiple fusion transcripts in a single prostate
cancer sample may reﬂect tumor heterogeneity or alterna-
tive splicing events. In order to map multiple fusion
junctions in a single assay, we redesigned the exon array
to include junction probes between exons 1 and 2 of the
TMPRSS2 gene and exons 1–6 of the ERG gene (Table 2).
The modiﬁed probe set showed very clearly that the
patient sample #15 had two fusion transcripts and also
revealed the relative ratios of the two fusion transcripts
through their respective signal intensities (Figure 3). In
this case, the two fusion transcripts are between exon 4
of the ERG fused to either exon 1 (T1G4) or exon 2
(T2G4) of the TMPRSS2. The signal intensity of T2G4
junction probe is weaker than that of the T1G4 junction
probe (Figure 3A), consistent with the intensities of the
probes within the exons. These two fusion transcripts are
very likely due to alternative splicing. Figure 4 summarizes
the cluster analysis (31) of the seven arrays; the results
are shown in Table 3. Multiple fusion variants were
found in 4/7 positive samples.
Table 3 also lists the percentages of cancer cells in the
tumors, the Gleason tumor grades and the detected var-
iants of TMPRSS2:ERG fusion transcripts. In this small
sample set, there is no clear association between tumor
Figure 2. Assay sensitivity. The VCaP total RNA was serially diluted in
a solution containing HeLa RNA to mimic the heterogeneous cell
population in primary tumors or human body ﬂuids. The total
amount of RNA for each reaction is 100ng. The laser power (PMT
600, 100% output) was adjusted to maximize the sensitivity of detec-
tion. Therefore, the intensity of the each expected feature (T1, G4, G5)
is at the saturated level. The signal disappeared when the VCaP RNA
was diluted from 1:3125 (32pg) to 1:15625 (6.4pg).
Table 2. Junction probes
Name Sequence
T1G1F CCTGGAGCGCGGCAGCCCCCGAGGGACATG
T1G2F CCTGGAGCGCGGCAGGTTATTCCAGGATCT
T1G3F CCTGGAGCGCGGCAGCCGTCAGGTTCTGAA
T1G4F CCTGGAGCGCGGCAGGAAGCCTTATCAGTT
T1G5F CCTGGAGCGCGGCAGATGCCACCCCCAAAC
T1G6F CCTGGAGCGCGGCAGATCCTACGCTATGGA
T2G1F ATGGCTTTGAACTCACCCCCGAGGGACATG
T2G2F ATGGCTTTGAACTCAGTTATTCCAGGATCT
T2G3F ATGGCTTTGAACTCACCGTCAGGTTCTGAA
T2G4F ATGGCTTTGAACTCAGAAGCCTTATCAGTT
T2G5F ATGGCTTTGAACTCAATGCCACCCCCAAAC
T2G6F ATGGCTTTGAACTCAATCCTACGCTATGGA
T1G1R CATGTCCCTCGGGGGCTGCCGCGCTCCAGG
T1G2R AGATCCTGGAATAACCTGCCGCGCTCCAGG
T1G3R TTCAGAACCTGACGGCTGCCGCGCTCCAGG
T1G4R AACTGATAAGGCTTCCTGCCGCGCTCCAGG
T1G5R GTTTGGGGGTGGCATCTGCCGCGCTCCAGG
T1G6R TCCATAGCGTAGGATCTGCCGCGCTCCAGG
T2G1R CATGTCCCTCGGGGGTGAGTTCAAAGCCAT
T2G2R AGATCCTGGAATAACTGAGTTCAAAGCCAT
T2G3R TTCAGAACCTGACGGTGAGTTCAAAGCCAT
T2G4R AACTGATAAGGCTTCTGAGTTCAAAGCCAT
T2G5R GTTTGGGGGTGGCATTGAGTTCAAAGCCAT
T2G6R TCCATAGCGTAGGATTGAGTTCAAAGCCAT
T, TMPRSS2; G, ERG. F, forward probe; R, reverse comple-
ment probe.
Figure 3. Detecting multiple fusion transcripts with junction probes.
(A) The exon probes alone show the sum of the signal derived from
individual transcripts. The junction probes reveal the species of the
transcripts. These two sets of data together are very useful to distin-
guish weak but true signals from otherwise random background signals.
(B) A scheme is presented to assist with data interpretation for (A),
which shows coexistence of T1G4 and T2G4 transcripts.
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larger study also showed that the presence of fusion tran-
script was associated with tumor stage but not tumor
grade (12). Consistent with the VCaP titration study
(Figure 2), the clinical assay can detect the fusion tran-
script when only 1% tumor cells is present in the prostate
tissue (sample 10).
FISHanalysis
We used FISH analysis to independently conﬁrm our
array approach. Our FISH procedure (28) employed
50-mer probes that were labeled with small haptens
for target hybridization in conjunction with individual
hapten-speciﬁc, quantum dot conjugated antibodies for
signal detection. The resolution of this method is  50kb.
We designed two probes for the FISH assays, one at the
promoter region of TMPRSS2 (green in Figure 5) and the
other at exon 2 of ERG (red in Figure 5). We observed
heterogeneity of the FISH patterns in some primary pros-
tate cancer samples (Figure 5). It is more diﬃcult to ﬁnd
interstitial deletions between TMPRSS2 and ERG in
tumor samples containing low percentages of cancer cells
by FISH. Therefore, we used samples that contained
480% cancer cells without detectable fusion genes to con-
ﬁrm the results of the arrays. The FISH experiments
revealed no genomic deletions at this location for all the
selected samples (#5, #7, #9, #19 and #20) that were simi-
larly nondeleted by array hybridization.
DISCUSSION
We have established a simple assay that can concurrently
proﬁle variants of TMPRSS2:ERG fusion transcripts
by combining a single RT–PCR with an exon array.
The modiﬁed ‘Round ABC’ protocol, which was
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Figure 4. Cluster analysis of seven prostate cancer samples having
fusion transcripts. The signal intensity of each feature is divided by
the intensity of a nonspeciﬁc control (herring sperm DNA) to normal-
ize the data for cluster analysis. The result is shown in Table 3. The
samples having similar fusion transcript variants were clustered
together by the program.
Table 3. The percentage of cancer cells in the tumors, the Gleason
tumor grades and the detected variants of TMPRSS2:ERG fusion
transcripts
Sample no. Cancer (%) Gleason grade Fusion transcripts
1 30 7 T1-G4; T2-G4
22 0 5
35 0 5
4 20 6 T1-G4
58 0 9
61 6
79 0 8
82 0 4
98 0 8
10 1 6 T1-G2
11 2 6
12 70 7
13 20 9 T1-G4
14 1 6
15 70 8 T1-G4; T2-G4
16 20 8
17 80 8 T1-G4; T2-G4
18 50 7 T1-G2; T1-G3; T1-G4
19 80 7
20 80 7
Figure 5. Heterogeneity of FISH patterns of interstitial deletion
between TMPRSS2 and ERG in a primary prostate tumor. An
unpaired green dot (TMPRSS2 probe, indicated by arrows) suggests
an interstitial deletion. Nonrandom variation of FISH patterns is
shown by the fact that most of the green and red signals (two diﬀerent
but nearby probes) are paired in each panel. This variation is expected
on a heterogeneous aneuploid cancer cell population, which often
makes it diﬃcult to distinguish meaningful events from random back-
ground aberrations.
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been widely adopted for chromatin immunoprecipitation
(ChIP) and whole-genome DNA microarrays (ChIP-chip)
(32,33) and Virochip (25,34) experiments, is a simple
and relatively unbiased ampliﬁcation procedure to semi-
quantitatively measure the fusion variants in a complex
sample. Previously, the same simple procedure was used
to obtain 83% (25kb/30kb) of the SARS coronavirus
genome with total nucleic acids isolated from a viral
culture (25).
The inclusion within the array of probes derived from
individual exons and potential fusion junctions simpliﬁes
the breakpoint mapping and increases the conﬁdence of
data interpretation (Figures 3 and 4). In contrast to some
reports that used multiple primers targeted to every poten-
tial fusion junction in hematological malignancies (35–38),
we used a single set of primers for target ampliﬁcation
(Figure 1). The fusion junctions were subsequently
decoded by array. This design signiﬁcantly reduces the
problems associated with primer dimers in the multiplex
PCR reaction, and creates more room for future assays
to include additional fusion genes. Furthermore, most
searches for fusion genes have focused on blood cancers,
because the cells can be puriﬁed before analysis. The appli-
cation of the previous methodologies is less useful for
highly complex solid tumors that are inevitably admixed
with normal cells. For example, a previously reported
MLLFusionChip could not be applied to samples with
cancer cells of55–10% in 1mg of total RNA (39).
The current assay should facilitate a thorough compi-
lation of the gene fusion variants in primary prostate
specimens, which may be useful for stratifying the aggres-
siveness of prostate cancer (13). In this regard, fusion var-
iants of EWS with another member of the ETS family,
FLI1, have been shown to be an independent predictor
of disease progression in Ewing’s sarcoma (40,41). It will
be of interest to compare in transfected cells the biological
activities of the diﬀerent TMPRSS2:ERG variants from
patients with contrasting clinical outcomes (41).
While some studies have suggested that the presence
of TMPRSS2:ERG fusions is associated with more
aggressive disease or higher Gleason tumor grade,
other investigators did not reach the same conclusion
(12,14,17,20,23,42). We also did not ﬁnd such an associa-
tion in a small series of samples. However, all of these
results are defective due to small sample size. The tech-
nology described here should make possible a larger scale
investigation to ﬁnd whether there is a correlation between
the aggressiveness of the disease and the presence of
speciﬁc fusion genes.
It is crucial to have true cancer-speciﬁc biomarkers for
early cancer detection as well as for minimal residual dis-
ease monitoring, which has been extensively demonstrated
in hematologic maligancies (43). Such biomarkers could
help to avoid under- or over-treatment. Thus, there is past
interest (24,44) in applying TMPRSS2:ERG fusion assays
for such application since PSA and many other markers
in development are not truly prostate cancer-speciﬁc (45).
A recent study reported a TMPRSS2:ERG assay with
a sensitivity of detecting 1600 VCaP cells (24). However,
this level of sensitivity might not be suﬃcient for broad
clinical application, especially with small biopsy specimens
or urine samples. We were able to achieve an assay sen-
sitivity of532pg of total RNA derived from VCaP cells,
an equivalent to 1–3 cells (Figure 2). Because our assay is
simple and amenable to automation, it is readily adaptable
to clinical studies. While it has been challenging to adapt
microarray-based technology to the clinic, some tests
(e.g. AmpliChip CYP450 and MammaPrint) have been
approved by FDA (46).
The same strategy can be applied to detect other less
prevalent fusion transcripts (TMPRSS2:ETV1 and
TMPRSS2:ETV4) in prostate cancer (2,5,6). In addition,
the exon array approach can also be applied to other
fusion genes, such as BCR-ABL in CML and clonal
Ig/TCR rearrangements in lymphocytic malignancies.
While this methodology development was motivated
by the clinical need, it is generally applicable to other
research requirements that are analogous to the situation
for detecting fusion genes in the single cell level when
a large excess of normal cells are present. For example,
a developmental biologist may use a similar approach to
screen mutants that have a desirable gene fusion when
direct gene targeting is not feasible.
There are some shortcomings of using RNA tran-
scripts as prostate cancer biomarkers, despite our ability
to achieve very sensitive detection of TMPRSS2:ERG
fusion variants. First, RNA is unstable and diﬃcult to
process in routine clinical assays. Second, commonly used
drugs that inhibit androgen growth pathways, including
GnRH agonists and testosterone antagonists, may dimin-
ish the production of the TMPRSS2:ERG mRNA fusion
transcript, thereby producing false-negative results in
patients on hormonal therapy with evolving androgen-
independent tumors. Indeed, it has been reported that
TMPRSS2:ERG mRNA fusion transcripts are not expres-
sed in androgen-independent tumors in spite of the pre-
sence of interstitial deletions in between TMPRSS2 and
ERG at chromosome 21q22 (10). While FISH is useful
for identifying genomic rearrangements, it has relatively
lower resolution and is diﬃcult to use in highly heteroge-
neous samples with small percentages of tumor cells.
We have recently developed a technology, designated
Primer Approximation Multiplex PCR (PAMP) for iden-
tifying breakpoints in genomic DNA without the need
to purify cancer cells from normal tissues (26). We are
optimizing this assay for detecting the breakpoints
between TMPRSS2 and ERG loci for primary prostate
tumors to overcome any potential problems associated
with RNA based biomarkers. In addition, the DNA-
based assay will provide information about whether
multiple fusion transcripts in a sample are derived from
alternative splicing or tumor heterogeneity. The best
approach may ultimately be to combine DNA and RNA
based assays in a common format.
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